Provided by Tiger Trade Technology Pte. Ltd.

Haemonetics

102.92
+0.97000.95%
Post-market: 102.920.00000.00%16:50 EDT
Volume:777.67K
Turnover:80.37M
Market Cap:4.68B
PE:50.20
High:104.37
Open:102.24
Low:101.61
Close:101.95
52wk High:109.57
52wk Low:47.32
Shares:45.45M
Float Shares:44.60M
Volume Ratio:1.28
T/O Rate:1.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.05
EPS(LYR):2.05
ROE:11.20%
ROA:6.60%
PB:5.59
PE(LYR):50.20

Loading ...

Press Release: Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026

Dow Jones
·
Jul 09

Citi adds ‘downside 90-day catalyst watch’ on Haemonetics

TIPRANKS
·
Jul 08

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

GlobeNewswire
·
Jul 06

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

GlobeNewswire
·
Jun 29

Haemonetics Price Target Maintained with a $84.00/share by BTIG

Dow Jones
·
Jun 26

Analysts Conflicted on These Healthcare Names: Haemonetics (HAE) and Health Catalyst (HCAT)

TIPRANKS
·
Jun 26

Pharvaris (PHVS) Is Up 6.0% After Strong Phase 3 Oral HAE Data With Novel Endpoint Introduction

Simply Wall St.
·
Jun 19

Haemonetics Price Target Maintained With a $84.00/Share by BTIG

Dow Jones
·
Jun 17

Haemonetics management to meet virtually with BTIG

TIPRANKS
·
Jun 17

Intellia Highlights Strong Phase 3 Lonvo-z HAE Results

TIPRANKS
·
Jun 15

Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026

GlobeNewswire
·
Jun 15

U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology

Reuters
·
Jun 15

How Investors Are Reacting To BioCryst (BCRX) Expanding Its HAE Prophylaxis Data Across Patient Groups

Simply Wall St.
·
Jun 15

BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

GlobeNewswire
·
Jun 12

Is Haemonetics’ (HAE) Apheresis Reorg Quietly Redefining Its Competitive Edge in Medical Devices?

Simply Wall St.
·
Jun 11

Pharvaris Announces Annual General Meeting of Shareholders

GlobeNewswire
·
Jun 11

Haemonetics announces annual shareholder meeting

Reuters
·
Jun 10

A Look At Intellia Therapeutics (NTLA) Valuation After Phase 3 HAE Success And Equity Raise

Simply Wall St.
·
Jun 10

Haemonetics: Buy Rating Reiterated as New Apheresis Reporting Boosts Transparency; $80 Price Target Maintained

TIPRANKS
·
Jun 08

Sector Update: Healthcare Stocks Higher Late Afternoon

MT Newswires Live
·
Jun 06